Framycetin
From Wikipedia, the free encyclopedia
Framycetin
Systematic (IUPAC) name
(2R,3S,4R,5R,6R)-5-amino-2-(aminomethyl)
-6-[(1R,2R,3S,4R,6S)-4,6-diamino-2-[(2S,3R,4S,5R)
-4-[(2R,3R,4R,5S,6S)-3-amino-6-(aminomethyl)
-4,5-dihydroxyoxan-2-yl]oxy-3-hydroxy
-5-(hydroxymethyl)oxolan-2-yl]oxy
-3-hydroxycyclohexyl]oxyoxane-3,4-diol
-6-[(1R,2R,3S,4R,6S)-4,6-diamino-2-[(2S,3R,4S,5R)
-4-[(2R,3R,4R,5S,6S)-3-amino-6-(aminomethyl)
-4,5-dihydroxyoxan-2-yl]oxy-3-hydroxy
-5-(hydroxymethyl)oxolan-2-yl]oxy
-3-hydroxycyclohexyl]oxyoxane-3,4-diol
Identifiers
Chemical data
Mol. mass 614.644 g/mol
Pharmacokinetic data
Therapeutic considerations
Routes oral, topical
Framycetin is an antibiotic of the aminoglycoside class similar to neomycin. Like neomycin, it has poor systemic absorption. It is used in topical preparations for infections of the skin, nose, ears, and eyes, often in combination with other antibacterial drugs and corticosteroids. It can also be used for gastrointestinal infections.
Framycetin is commonly sold as Soframycin and Sofra-Tulle.
This pharmacology-related article is a stub. You can help Wikipedia by expanding it.
